Evozyne
Molly Evans is a Research Scientist II at Evozyne, having progressed from Research Scientist I since September 2021. Prior experience includes a role as a Postdoctoral Scientist at Abbott, where nucleic acid testing approaches for infectious disease detection were developed from November 2020 to August 2021. Previous positions include Postdoctoral Researcher at Northwestern University, focusing on high-throughput RNA structure probing experiments from September 2017 to November 2020, and Graduate Student at the University of Chicago, where tRNA base methylation identification and quantification were performed, alongside other projects from September 2012 to August 2017. Early career experiences include a Postbac IRTA at The National Institutes of Health and an Undergraduate Researcher role at Carnegie Mellon University. Molly Evans holds a PhD in Biochemistry and Molecular Biophysics from the University of Chicago and a BS in Biology from Carnegie Mellon University.
Evozyne
1 followers
Evozyne combines evolution and deep learning technology to create highly functional novel proteins — Natural Machines™ — to solve longstanding challenges in therapeutics and sustainability. By amplifying a protein’s function based on the rules of nature, we address complex, high-impact problems. From developing life-changing patient treatments to making carbon capture a reality, Evozyne is committed to making a healthier, more sustainable world.